SCHEMBL408608

SCHEMBL408608

O=C(O)CC1CCC(c2ccc(-c3ccc4oc(Nc5ccccc5)nc4c3)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 18/20 1.00
SOAT2 O75908 5/20 0.56
SOAT1 P35610 2/20 0.55
HDAC6 Q9UBN7 2/20 0.51
CYP2C9 P11712 1/20 0.48
DGAT2 Q96PD7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL408609 1.00 DGAT1 (1.00) DGAT1SOAT2SOAT1HDAC6CYP2C9
SCHEMBL13664077 0.81 DGAT1 (0.68) DGAT1
SCHEMBL19292677 0.81 DGAT1 (0.68) DGAT1
SCHEMBL180819 0.81 DGAT1 (0.68) DGAT1
SCHEMBL14617030 0.81 DGAT1 (0.68) DGAT1
SCHEMBL15872159 0.80 DGAT1 (0.67) DGAT1
SCHEMBL10197900 0.78 DGAT1 (0.70) DGAT1SOAT2SOAT1
SCHEMBL410032 0.78 DGAT1 (0.70) DGAT1SOAT2SOAT1
SCHEMBL410033 0.78 DGAT1 (0.70) DGAT1SOAT2SOAT1
SCHEMBL180670 0.78 DGAT1 (0.63) DGAT1SOAT2SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2012-01-26 US disclosed
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2012-01-26 US disclosed
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE DGAT2, DGAT1, LCAT DGAT1 2/4885SOAT2 9/4885SOAT1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.